FUSION PHARMACEUTICALS

Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.

Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year.

GLP-1 receptor agonists like semaglutide and tirzepatide showed potential beyond diabetes and weight loss, including cardiovascular and mental health benefits.